Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7549052 | 0.94 | TSHR (0.33) | TSHR | |
| SCHEMBL28348241 | 0.87 | — | — | |
| Sulfuric Acid SCHEMBL4752456 | 0.83 | CYP3A4 (0.30) | TSHR | |
| SCHEMBL15969554 | 0.81 | TSHR (0.31) | TSHR | |
| Iodide SCHEMBL11050168 | 0.79 | OPRM1 (0.37) | TSHR | |
| Hydrochloric Acid SCHEMBL11190139 | 0.78 | LMNA (0.38) | TSHR | |
| Water SCHEMBL7941486 | 0.74 | SLC22A1 (0.33) | TSHR | |
| SCHEMBL1994789 | 0.71 | TSHR (0.38) | TSHR | |
| SCHEMBL31374472 | 0.71 | DNM1 (0.39) | TSHR | |
| Bromide SCHEMBL29773378 | 0.70 | SLC22A1 (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842424-B1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | UNIV COLUMBIA (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3842424-A1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | The Trustees of Columbia University in the City of New York (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3521284-B1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10428047-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3521284-A1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2968322-B1 | MAP KINASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9783525-B2 | Map kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| EP-2968322-A2 | MAP KINASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145485-A2 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428047-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | TSHR 2521/4885KDM4E 4282/4885PMP22 2481/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | TSHR 4665/4885KDM4E 2045/4885PMP22 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.